

Resource Summary Report

Generated by [ASWG](#) on Aug 5, 2026

Indelocator

RRID:SCR_005258

Type: Tool

Proper Citation

Indelocator (RRID:SCR_005258)

Resource Information

URL: <http://www.broadinstitute.org/cancer/cga/indelocator>

Proper Citation: Indelocator (RRID:SCR_005258)

Description: A software tool for calling short indels in next generation sequencing data.

Abbreviations: Indelocator

Resource Type: software resource

Resource Name: Indelocator

Resource ID: SCR_005258

Alternate IDs: OMICS_00098

Record Creation Time: 20220129T080229+0000

Record Last Update: 20260801T190249+0000

Ratings and Alerts

No rating or validation information has been found for Indelocator.

No alerts have been found for Indelocator.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 44 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Stevens LE, et al. (2023) JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States. *Cancer research*, 83(2), 264.

Pradat Y, et al. (2023) Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer. *Cancer discovery*, 13(5), 1116.

Farshidfar F, et al. (2022) Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis. *Nature communications*, 13(1), 898.

Lee SH, et al. (2020) Mutation Analysis of Colorectal and Gastric Carcinomas Originating from Adenomas: Insights into Genomic Evolution Associated with Malignant Progression. *Cancers*, 12(2).

Lin YL, et al. (2020) Establishment of patient-derived xenograft model of peritoneal mucinous carcinomatosis with signet ring cells and in vivo study on the efficacy and toxicity of intraperitoneal injection of 5-fluorouracil. *Cancer medicine*, 9(3), 1104.

Lakomy DS, et al. (2020) Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers. *Clinical and translational radiation oncology*, 21, 56.

Färkkilä A, et al. (2020) Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. *Nature communications*, 11(1), 1459.

Bai X, et al. (2020) Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study. *Journal for immunotherapy of cancer*, 8(1).

Enache OM, et al. (2020) Cas9 activates the p53 pathway and selects for p53-inactivating mutations. *Nature genetics*, 52(7), 662.

Fomchenko EI, et al. (2019) DNMT3A co-mutation in an IDH1-mutant glioblastoma. *Cold Spring Harbor molecular case studies*, 5(4).

Zhang BD, et al. (2019) Loss of PTPN4 activates STAT3 to promote the tumor growth in rectal cancer. *Cancer science*, 110(7), 2258.

Ng SY, et al. (2018) Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. *Nature communications*, 9(1), 2024.

Priolo C, et al. (2018) Impairment of gamma-glutamyl transferase 1 activity in the metabolic pathogenesis of chromophobe renal cell carcinoma. *Proceedings of the National Academy of Sciences of the United States of America*, 115(27), E6274.

de Velasco G, et al. (2018) Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma. *British journal of cancer*, 118(9), 1238.

Ben-David U, et al. (2018) Genetic and transcriptional evolution alters cancer cell line drug response. *Nature*, 560(7718), 325.

Hellmann MD, et al. (2018) Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. *Cancer cell*, 33(5), 843.

Fomchenko EI, et al. (2018) De novo MYH9 mutation in congenital scalp hemangioma. *Cold Spring Harbor molecular case studies*, 4(4).

Melendez-Zajgla J, et al. (2018) Genomics of a pediatric ovarian fibrosarcoma. Association with the DICER1 syndrome. *Scientific reports*, 8(1), 3252.

Krøigård AB, et al. (2018) Identification of metastasis driver genes by massive parallel sequencing of successive steps of breast cancer progression. *PloS one*, 13(1), e0189887.

Corso S, et al. (2018) Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts. *Neoplasia* (New York, N.Y.), 20(5), 443.